This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of July 2026. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.
| Item | Value |
|---|---|
| Country |
| Cause area | Count | Median | Mean | Minimum | 10th percentile | 20th percentile | 30th percentile | 40th percentile | 50th percentile | 60th percentile | 70th percentile | 80th percentile | 90th percentile | Maximum |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 10 | 528,370 | 1,119,585 | 320,265 | 320,265 | 322,663 | 365,127 | 528,370 | 528,370 | 645,267 | 645,267 | 1,511,994 | 1,801,900 | 4,526,625 |
| Global health | 9 | 528,370 | 741,025 | 320,265 | 320,265 | 322,663 | 365,127 | 528,370 | 528,370 | 645,267 | 645,267 | 1,511,994 | 1,801,900 | 1,801,900 |
| FIXME | 1 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 | 4,526,625 |
| Donor | Total | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation (filter this donee) | 6,669,222.00 | 365,127.00 | 2,444,828.00 | 1,511,994.00 | 1,290,534.00 | 1,056,739.00 | 0.00 |
| Wellcome Trust (filter this donee) | 4,526,625.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,526,625.00 |
| Total | 11,195,847.00 | 365,127.00 | 2,444,828.00 | 1,511,994.00 | 1,290,534.00 | 1,056,739.00 | 4,526,625.00 |
There are no documents associated with this donee.
Graph of top 10 donors (for donations with known year of donation) by amount, showing the timeframe of donations
| Donor | Amount (current USD) | Amount rank (out of 10) | Donation date | Cause area | URL | Influencer | Notes |
|---|---|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | 365,127.00 | 8 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to establish a portfolio of small molecule hits, leads and clinical assets against drug-resistant shigellosis and other enteric bacterial pathogens; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Bill and Melinda Gates Foundation | 320,265.00 | 10 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to generate an alternative tool for malaria control which can be integrated into existing approaches which target disease elimination; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Bill and Melinda Gates Foundation | 1,801,900.00 | 2 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to progress a novel TB drug candidate through preclinical studies.. Progression of a novel cholesterol dependent antitubercular (GSK286) through GLP-Tox studies. Investment start date: 8/18/2017 to end date: 7/31/2019. Grantee name: GlaxoSmithKline I+D, S; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Bill and Melinda Gates Foundation | 322,663.00 | 9 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to establish a portfolio of small molecule hits, leads and clinical assets against drug-resistant shigellosis and other enteric bacterial pathogens; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Bill and Melinda Gates Foundation | 1,511,994.00 | 3 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to further research intended to increase the efficacy of drug treatment of malaria and ultimately reduce the public health threat posed by malaria in developing countries; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Bill and Melinda Gates Foundation | 645,267.00 | 4 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to access a first in class technology platform to identify the molecular targets of up to 10 anti-TB and anti-malaria lead compounds for the benefit of the wider Malaria and TB drug discovery communities; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Bill and Melinda Gates Foundation | 645,267.00 | 4 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to access a first in class technology platform to identify the molecular targets of up to 10 anti-TB and anti-malaria lead compounds for the benefit of the wider Malaria and TB drug discovery communities; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Bill and Melinda Gates Foundation | 528,369.50 | 6 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to access a first in class technology platform to identify the molecular targets of up to 10 anti-TB and anti-malaria lead compounds for the benefit of the wider Malaria and TB drug discovery communities; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Bill and Melinda Gates Foundation | 528,369.50 | 6 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to access a first in class technology platform to identify the molecular targets of up to 10 anti-TB and anti-malaria lead compounds for the benefit of the wider Malaria and TB drug discovery communities; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| Wellcome Trust | 4,526,625.00 | 1 | FIXME | https://wellcome.ac.uk/sites/default/files/wellcome-grants-awarded-2000-2016.xlsx | -- | GSK Diseases of the Developing World Discovery Engine. Affected regions: International; affected countries: Spain. |